Abstract Number: 1413 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Background/Purpose: In the RAPID1 randomized controlled trial (RCT; NCT00152386),1 certolizumab pegol (CZP) every 2 weeks (Q2W) plus MTX over 52 weeks (wks) provided rapid improvements…Abstract Number: 1414 • 2013 ACR/ARHP Annual Meeting
Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Background/Purpose: The safety and efficacy of subcutaneous golimumab (GLM)+/-MTX has been evaluated through 2yrs in a phase 3 trial (GO-FORWARD) of pts with active rheumatoid…Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…Abstract Number: 1416 • 2013 ACR/ARHP Annual Meeting
Safety and Efficacy Of Subcutaneous Golimumab In Chinese Patients With Active Rheumatoid Arthritis Despite MTX Therapy: Results From a Randomized, Placebo-Controlled, Phase 3 Trial
Background/Purpose: Assess safety and efficacy of GLM+MTX over 1yr in a multicenter, randomized, placebo (PBO)-controlled study of Chinese pts with active RA despite MTX therapy.…Abstract Number: 1390 • 2013 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3n (eta) In Rheumatoid Arthritis and Arthritogenic Viral Infections
Background/Purpose: The 14-3-3 proteins are ubiquitously-expressed intracellular chaperonins. Expression of the η (eta) isoform is restricted to synovial and CNS tissues. Extracellular 14-3-3η induces proinflammatory…Abstract Number: 1377 • 2013 ACR/ARHP Annual Meeting
Decoy Receptor 3 Regulates the Expression of Tryptophan Hydroxylase TPH1 in Rheumatoid Synovial Fibroblasts
Background/Purpose: Tryptophan hydroxylase (TPH) which catalyzes the hydroxylation of L-tryptophan is the rate-limiting enzyme involved in the synthesis of serotonin. TPH has two isoforms; TPH1…Abstract Number: 1378 • 2013 ACR/ARHP Annual Meeting
Associations Of Periodontitis (PD) With Established Seropositive Rheumatoid Arthritis are Independent of Smoking and Other Risk Factors
Background/Purpose: Periodontitis (PD) has been proposed as a risk factor in RA. Reports have suggested that this association may be due to confounding from smoking…Abstract Number: 1379 • 2013 ACR/ARHP Annual Meeting
Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
Background/Purpose: Biological agents inhibiting proinflammatory cytokines, especially IL-6 and TNFa, have brought a great impact in the treatment of rheumatoid arthritis (RA). In addition, CTLA4-Ig…Abstract Number: 1380 • 2013 ACR/ARHP Annual Meeting
Histone Modifications In The Interluekin-6 Gene Promoter Region Of Rheumatoid Arthritis Synovial Fibroblasts
Background/Purpose: , Rheumatoid arthritis (RA) is a disease of unknown origin, which develops continuous inflammation and progressive joint destruction resulting from an autoimmune response mainly…Abstract Number: 1381 • 2013 ACR/ARHP Annual Meeting
The ZC3HC1 rs11556924 Polymorphism Is Associated With Increased Carotid Intima-Media Thickness In Patients With Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex polygenic disease associated with chronic inflammation, accelerated atherosclerosis and increased cardiovascular (CV) mortality. A recent meta-analysis has described…Abstract Number: 1382 • 2013 ACR/ARHP Annual Meeting
The 11q23.3 Genomic Region – rs964184- Is Associated With Cardiovascular Disease In Patients With Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis and high risk of cardiovascular (CV) disease. A recent meta-analysis has…Abstract Number: 1383 • 2013 ACR/ARHP Annual Meeting
Validation Of Popliteal Lymph Node Phenotype and Bin Expansion As Biomarkers Of Rheumatoid Arthritis Knee Flare
Background/Purpose: Factors precipitating joint flare in rheumatoid arthritis (RA) patients are poorly understood. Contrast enhanced (CE) MRI studies in murine models have identified popliteal lymph…Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting
Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting
A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting
Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…